Epistem Limited

disease & therapeutic research models

Inflammatory Bowel Disease

GI Toxicity and Mucositis

Immune Cell Assays

Rheumatoid Arthritis

services

Gene Expression Analysis

Histology and IHC Services

Laser Capture Microdissection

Analytical Services

Plucked Hair Analysis

Spotlight On...

Heterogeneous cellular response to ionising radiation revealed by single cell …
In this study, the authors used single-cell transcriptomic analysis to determine the effects of ionising radiation in a breast cancer cell line.…
Targeting Phosphatidylserine Enhances the Anti-tumour Response to …
In this study, researchers detected phosphatidylserine expression on the surface of immune cells in the tumour microenvironment and found targeted…
Tumour Infiltrating Effector Memory Antigen-Specific CD8⁺ …
An oncology study to determine if infiltrating T-cells could be used as a biomarker for response to immune checkpoint inhibitor…
The serotonin reuptake transporter is reduced in the epithelium of active …
Our team recently came across an IBD study which demonstrated for the first time that the serotonin reuptake transporter protein is downregulated in…
Human ileal organoid model recapitulates clinical incidence of diarrhoea …
In this study the authors described the characterisation of a human 3D enteroid culture model for assessing drug-induced gastro-intestinal…

Announcements

NEWS: Epistem licence Hubrecht Organoid Technology to expand preclinical toxicology service portfolio
2019-07-15
Epistem Limited has announced the expansion of its in vitro model portfolio by the completion of an agreement with Hubrecht Organoid Technology (HUB)…
NEWS: 10 Years GCLP Accreditation at Epistem
2019-01-11
We are pleased to announce the successful GCLP re-accreditation of our laboratories.

© 2018, 2021 Epistem Ltd.

site map | privacy policy | terms of use | contact us

Call us on +44 (0)161 850 7600 or email info@epistem.co.uk

Accelerating Drug Development with Innovative Services

This site uses cookies for tracking and statistical purposes. Please read our privacy policy for more information.

Don't show this again